Andrea van Elsas

Dr. van Elsas is currently Chief Scientific Officer of Aduro Biotech, Inc. He joined Aduro following the 2015 acquisition of BioNovion, a company he co-founded that was focused on the development of innovative therapeutic antibodies in the field of immuno-oncology. In addition, Dr. van Elsas is VP Research of AM Pharma, a company developing recombinant human Alkaline Phosphatase for inflammatory diseases, and he supports Gilde Healthcare as an Operational Partner in the evaluation of investment opportunities.

He currently serves on the Board of Lava Therapeutics, and on the Scientific Advisory Board of InteRNA Technologies. He holds a Ph.D. in Immunology and Oncology from the University of Leiden.